Phase 4 N=113 Anti-HIV Medications for People Recently Infected With HIV
HIV Infections
Primary: Total Treatment-free Time to Initiation of Permanent HAART — 18; 18 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=215 Incidence of HANA Conditions in HIV-infected Individuals
HIV · Metabolic Syndrome · Osteopenia
Primary: Prevalences of HIV-associated Non-AIDS Conditions (HANA) — 69; 15; 30; 4 Participants — p=0.244
Phase 1 N=23 HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease
Aids, Cdc Group I
Primary: Tolerability and Safety of the Treatment. — 0; 0 participants
Phase 4 N=1,771 Antiretroviral Therapy for Advanced HIV Disease in South Africa
HIV
Primary: Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens. — 93; 77; 70; 80 participants
N/A N=114 Analytical Treatment Interruption in HIV Positive Patients
HIV-1 Infection
Primary: Assessment of the Number of Participants With a HIV Plasma Viral Load Below the Lower Limit of Detection 48 Weeks Following Interruption of Antiretroviral Treatment — 0…
Phase 4 N=28 Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients
HIV Infections
Primary: Change From Baseline in CD4 Count at 48 Weeks — 192; 205 cells/uL
Phase 4 N=16 HIV Persistence and Viral Reservoirs
HIV · HIV Infections
Primary: Mean Change in Estimated Ultrasensitive Plasma HIV RNA Levels Between Baseline and Week 24 — 66 fold decrease in signal/cutoff ratio
N/A N=42 New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients
HIV Infections
Primary: Combined Endpoint Including HIV RNA and HIV DNA — 0; 0 Participants
N/A N=37 Cardiovascular Prevention for Persons With HIV
HIV Infection · Cardiovascular Disease Risk
Primary: Number of Participants Who Stated (by Self-report) That They Had Side Effects — 1; 0; 2; 1 participants
Phase 2 N=68 Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial
HIV-1
Primary: Percentage of Participants With Clonal Expansion of Cells With a Predominant OZ1 Insertion Site — 0 Percentage of participants
N/A N=257 Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults
HIV Infections
Primary: Confirmed Virologic Failure at or Prior to Week 48 — 95; 105; 34; 23 participants — p=0.133
Phase 2 N=22 VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1
HIV Infections
Primary: Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) — -1.17; -2.15; -2.31; -0.28 Copies per milliliter…
Phase 3 N=4 Therapy to Elevate CD4 Counts in HIV-1 Disease
HIV Disease
Primary: CD4/CD8 Ratio — 0.44 Ratio
Phase 3 N=89 Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure
HIV Infection
Primary: Proportion of Participants With Treatment Failure — 0.0682; 0.0667 proportion of participants
Phase 2 N=17 Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy
HIV Infection
Primary: Occurrence of Grade ≥ 1 Adverse Events (AEs) — 5; 26; 4 events
N/A N=282,368 Kaiser Permanente HIV Cohort Study
HIV · AIDS
Primary: Incidence Rate of Malignancies — 513; 3; 238; 20 malignancies per 100,000 person-years — p=<0.001
Phase 2 N=29 Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients
Hepatitis C · HIV Infections
Primary: Number of Participants With Sustained Virologic Response (SVR) — 11; 11 participants
N/A N=8,202 HIV Cohort Study At Johns Hopkins University, University of North Carolina at Chapel Hill and Vanderbilt University
HIV · AIDS
Primary: Incidence Rate of Malignancies — 0.30; 0.27; 0.02; 0.62 malignancies per 100 person-years
Phase 2 N=12 Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma
AIDS-Related-Primary Central Nervous System Lymphoma
Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants
Phase 4 N=6 Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C
Hepatitis C, Chronic · HIV
Primary: Proportion of Subjects With Sustained Virologic Response (SVR12) — 3; 2 Participants
N/A N=250 Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
HIV Infections · Memory
Primary: The Prevalence of Neurocognitive Deficits Among HIV-positive Patients as Defined by the Global Deficit Score Based on the Neuropsychological Testing Battery and to…
Phase 2 N=24 Randomized Placebo-Controlled Trial of Atorvastatin in HIV-Positive Patients Not on Antiretroviral Therapy
HIV
Primary: Change in Human Immunodeficiency Virus 1 (HIV-1) Ribonucleic Acid (RNA) Levels — 0; 0; -0.03; -0.08 Log10 copies/ml plasma
Phase 2 N=14 A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults
HIV Infections
Primary: Part 1: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Day 11 — -8605.8; -100719.8; -3406.5 Copies per milliliter
Phase 2 N=7 Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
HIV Infection
Primary: Pre- and Post- Interferon Alpha on Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) — 670; 180; 90; 130 # of copies of HIV RNA/million cells
Phase 1 N=21 MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy
HIV-1-infection
Primary: Number of Participants With Treatment-Emerging Adverse Events — 1; 1; 4; 3 Participants
Phase 2 N=80 The Role of Probiotics in HIV Patients With Immunological Non-Responder
HIV Infections · Immunological Abnormality
Primary: CD4+ Level — 162.3; 50.5; 143.3; 69.9 cell/μL — p=0.02
N/A N=368 CSP #512 - Options in Management With Anti-Retrovirals
AIDS · HIV Infections
Primary: Number of Participants With New or Recurrent AIDS Event, or Death — 83; 82 participants — p=0.69
Phase 1 N=16 Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults
HIV-1
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 3 Days After VRC01LS or VRC07-523LS Administration — 7; 6; 0; 3 Participants
N/A N=605 Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected Patients
HIV Infections
Primary: Number of Participants With Treatment Emergent Adverse Events (AE) and All Serious AEs — 168; 110; 51; 10 participants
Phase 2 N=30 Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients
HIV-2 Infection
Primary: Percentage of Participants in Therapeutic Success — 40 percentage of participants